SCHEMBL4458878

SCHEMBL4458878

O=C(c1ccccn1)C1CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.58
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
CYP1A2 P05177 1/20 0.51
GAA P10253 1/20 0.51
LMNA P02545 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
GRM4 Q14833 2/20 0.50
NAPRT Q6XQN6 1/20 0.50
P4HTM Q9NXG6 1/20 0.50
GRM5 P41594 1/20 0.50
EPHX2 P34913 1/20 0.49
PLA2G1B P04054 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449861 0.98 CYP3A4 (0.58) PKMCYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL5042317 0.95 CYP3A4 (0.58) PKMCYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL5928876 0.91 CES2 (0.57) PKMCYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL4673995 0.84 CES2 (0.50) PKMCYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL24131018 0.83 CES2 (0.48) PKMCYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL38661039 0.83 CES2 (0.58) PKMCYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL30137728 0.83 PDE10A (0.58) PKMCYP3A4CYP2C9ALDH1A1NPC1
SCHEMBL408199 0.83 CES2 (0.48) PKMCYP3A4CYP2C9ALDH1A1CES2
Hydrochloric Acid SCHEMBL439311 0.81 KMT2A (0.47) PKMCYP3A4CYP2C9ALDH1A1CES2
SCHEMBL20412775 0.81 RAB9A (0.52) PKMCYP3A4CYP2C9SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233799-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2021-05-19 EP disclosed
US-10752588-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-08-25 US disclosed
EP-3611164-A1 PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT Mitsui Chemicals Agro, Inc. (JP) 2020-02-19 EP disclosed
US-20190345105-A9 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-11-14 US disclosed
US-20190023656-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2019-01-24 US disclosed
EP-3233799-A1 DOPAMINE D2 RECEPTOR LIGANDS The Broad Institute Inc. (US) 2017-10-25 EP disclosed
WO-2016100823-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 WO disclosed
EP-1425262-B1 Acylthiols and compositions thereof as anti-HIV and anti-retroviral agents GOV OF USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES NAT INST OF HEALTH (US) 2014-01-08 EP disclosed
US-8076372-B2 Acythiols and component thiol compositions as anti-HIV and anti-retroviral agents GOVERNMENT OF THE UNITED STATES (US) 2011-12-13 US disclosed
US-20090247473-A1 ACYTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS THE GOVERNMENT OF THE U.S.A.,AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) 2009-10-01 US disclosed
US-7112680-B2 Heterocyclic hydrazones for use as anti-cancer agents AUSTRIA WIRTSCHAFTSSERVICE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (AT) 2006-09-26 US disclosed
EP-1425262-A4 ACYLTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS US GOV HEALTH & HUMAN SERV (US) 2006-03-08 EP disclosed
US-20050020831-A1 Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents GOVERNMENT OF THE UNITED STATES 2005-01-27 US disclosed
EP-1425262-A1 ACYLTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS The Gov. of USA, as represented by the Secretary, Dept. of Health and Human services, National Institutes of Health (US) 2004-06-09 EP disclosed
CN-1146548-C Isoxazolyl-and isoxazolinyl-substituted benzoylcyclohexanediones, method for the production thereof and use thereof as herbicides and plant growth regulators �Ϻ���ͨ��ѧ 2004-04-21 CN disclosed
US-20030166658-A1 Heterocyclic hydrazones for use as anti-cancer agents EASMON, JOHNNY, OF INSTITUT FUR PHARMAZIE (AT) 2003-09-04 US disclosed
EP-1286987-A1 HETEROCYCLIC HYDRAZONES FOR USE AS ANTI-CANCER AGENTS Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung (AT) 2003-03-05 EP disclosed
WO-2003014062-A1 ACYLTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2003-02-20 WO disclosed
CN-1364160-A Isoxazolyl-and isoxazolinyl-substituted benzoylcyclohexanediones, their preparation and their use as herbicides and plant growth regulators AVENTIS CROPSCIENCE GMBH (DE) 2002-08-14 CN disclosed
WO-2001094340-A1 HETEROCYCLIC HYDRAZONES FOR USE AS ANTI-CANCER AGENTS INNOVATIONSAGENTUR GESELLSCHAFT M.B.H. (AT) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345105-A9 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 PKM 3719/4885CYP3A4 3886/4885CYP2C9 4447/4885
US-20190023656-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 PKM 3719/4885CYP3A4 3886/4885CYP2C9 4447/4885
US-20030166658-A1 Heterocyclic hydrazones for use as anti-cancer agents HDAC5, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 PKM 2101/4885CYP3A4 1396/4885CYP2C9 3190/4885
US-10752588-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 PKM 3719/4885CYP3A4 3886/4885CYP2C9 4447/4885
US-20090247473-A1 ACYTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS ZC3HAV1, ZFP3, ATL3 PKM 4166/4885CYP3A4 4506/4885CYP2C9 4705/4885
US-20050020831-A1 Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents ZC3HAV1, ACAT2, ACAT1 PKM 4195/4885CYP3A4 4500/4885CYP2C9 4738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.